Pyoderma gangrenosum
Pyoderma gangrenosum är en sällsynt inflammatorisk hudsjukdom där smärtsamma pustler eller knölar utvecklas till sår som växer gradvis. Pyoderma gangrenosum är inte smittsamt. Behandling kan innefatta kortikosteroider, ciklosporin eller olika monoklonala antikroppar. Även om sjukdomen kan drabba personer i alla åldrar, är den vanligast hos personer i 40‑ och 50‑årsåldern.
☆ AI Dermatology — Free Service
I Stiftung Warentest-resultaten 2022 från Tyskland var konsumentnöjdheten med ModelDerm bara något lägre än med betalda telemedicinkonsultationer.
I Stiftung Warentest-resultaten 2022 från Tyskland var konsumentnöjdheten med ModelDerm bara något lägre än med betalda telemedicinkonsultationer.
På benet hos en person med ulcerös kolit.
relevance score : -100.0%
ReferencesPyoderma gangrenosum är en sällsynt hudsjukdom som ger smärtsamma sår med röda eller lila kanter. Den klassificeras som en inflammatorisk sjukdom och tillhör gruppen neutrofila dermatoser. Orsaken är komplex och involverar både medfödd och adaptiv immunitet hos genetiskt predisponerade individer. På senare tid har forskare fokuserat på hårsäcken som en möjlig utgångspunkt för sjukdomen.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum är en sällsynt hudsjukdom som ger extremt smärtsamma sår. Även om orsaken fortfarande är oklar vet vi att den innebär ökad aktivitet hos vissa immunceller. Att behandla sjukdomen är fortfarande svårt. Det finns flera läkemedel som hämmar immunförsvaret eller modifierar dess aktivitet. Utöver detta fokuserar vi på sårläkning och smärthantering. Kortikosteroider och cyclosporine är ofta förstahandsvalet, men på senare tid har forskningen ökat kring biologiska terapier, exempelvis TNF‑α‑hämmare. Dessa biologiska läkemedel föredras i allt högre grad, särskilt hos patienter med andra inflammatoriska tillstånd, och de kan användas tidigare i sjukdomsförloppet.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
